The DOI matches its Crossref record; the references it cites are not checked yet.
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial
Open accessAbstract
Staphylococcus aureus colonizes patients with atopic dermatitis (AD) and exacerbates disease by promoting inflammation. The present study investigated the safety and mechanisms of action of Staphylococcus hominis A9 (ShA9), a bacterium isolated from healthy human skin, as a topical therapy for AD. ShA9 killed S. aureus on the skin of mice and inhibited expression of a toxin from S. aureus (psmα) that promotes inflammation. A first-in-human, phase 1, double-blinded, randomized 1-week trial of topical ShA9 or vehicle on the forearm skin of 54 adults with S. aureus-positive AD (NCT03151148) met its primary endpoint of safety, and participants receiving ShA9 had fewer adverse events associated with AD. Eczema severity was not significantly different when evaluated in all participants treated with ShA9 but a significant decrease in S. aureus and increased ShA9 DNA were seen and met secondary endpoints. Some S. aureus strains on participants were not directly killed by ShA9, but expression of mRNA for psmα was inhibited in all strains. Improvement in local eczema severity was suggested by post-hoc analysis of participants with S. aureus directly killed by ShA9. These observations demonstrate the safety and potential benefits of bacteriotherapy for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While well tolerated, ShA9 also induced a modest improvement of skin lesions as measured by EASI and SCORAD43.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [43]
In the citing paper
“Following the same strategy of bacteriotherapy, topical application of a lyophilized strain of Staphylococcus hominis A9 (ShA9) with the dual activity of killing Staphylococcus aureus and inhibiting the production of S. aureus-derived toxins, allowed the microbiome to recover.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [43]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 60 · Cited by 333
Metadata
- Authors
- Nakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., Jepson, B., Calatroni, A., David, G., Ramirez-Gama, M., Taylor, P., Leung, D. Y. M., & Gallo, R. L.
- Affiliations
- University of California San Diego (US)
- Rho (United States) (US)
- National Jewish Health (US)
- Corresponding author
- Gallo, Richard L.
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-02-22
- Volume
- 27
- Issue
- 4
- Pages
- 700-709
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8052297
- OpenAlex
- W3129601032
- Cited by
- 333
- References
- 60
- Citations by year
- 2026: 60 · 2025: 73 · 2024: 58 · 2023: 51 · 2022: 59 · 2021: 31
- FWCI
- 43.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI117673 and 1UM1AI151958, R37AI052453, U19AI117673, R01AI153185)
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR076082)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR002535)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- atopic dermatitis, bacterial therapy, Staphylococcus aureus, skin commensal bacteria, topical treatment, Staphylococcus aureus colonization, eczema severity, first-in-human safety
- MeSH terms
- Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Animals, Bacterial Proteins, Bacteriocins, Dermatitis, Atopic, Humans, Inflammation, Mice, Inbred BALB C, Microbial Sensitivity Tests, Middle Aged, Peptides, Cyclic, Skin, Staphylococcal Infections, Staphylococcus aureus, Transcription, Genetic, Colony Count, Microbial, Reproducibility of Results, Treatment Outcome, Virulence Factors, Staphylococcus hominis, Microbial Viability, Mice, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. https://app.cochat.ai/papers/10.1038/s41591-021-01256-2
- The paper
- Nakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., Jepson, B., Calatroni, A., David, G., Ramirez-Gama, M., Taylor, P., Leung, D. Y. M., & Gallo, R. L. (2021). Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01256-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.